Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance

Overview

Journal J Liver Cancer

Date 2023 Jun 29

PMID 37383054

Authors

So Hyun Park

Bohyun Kim

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) surveillance is recommended when the annual incidence of HCC exceeds 1.5%. In 2018, several international guidelines included alternative surveillance modalities, such as computed tomography and magnetic resonance imaging (MRI), as alternatives for patients with inadequate surveillance with an ultrasound. Currently, abbreviated MRI selectively includes several key sequences and is emerging as an effective tool for HCC surveillance with reduced cost and scan time and the required diagnostic performance. The incidence of HCC substantially impacts the benefits of surveillance in terms of cost-effectiveness. Therefore, we need to individualize imaging surveillance of HCC, tailor screening, and determine risk-stratified strategies. The purpose of this article was to present a brief overview of the diagnostic performance and cost-effectiveness of liver MRI as an HCC surveillance tool.

Citing Articles

A Post-International Gastrointestinal Cancers' Conference (IGICC) Position Statements.

Yalcin S, Lacin S, Kaseb A, Peynircioglu B, Cantasdemir M, Cil B J Hepatocell Carcinoma. 2024; 11:953-974.

PMID: 38832120 PMC: 11144653. DOI: 10.2147/JHC.S449540.

Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis.

Yu S, Yoo J, Lee D, Kim S, Cho E, Kim S Biomedicines. 2023; 11(2).

PMID: 36830919 PMC: 9953123. DOI: 10.3390/biomedicines11020382.

Potential of a Non-Contrast-Enhanced Abbreviated MRI Screening Protocol (NC-AMRI) in High-Risk Patients under Surveillance for HCC.

Willemssen F, de Lussanet de la Sabloniere Q, Bos D, IJzermans J, de Man R, Dwarkasing R Cancers (Basel). 2022; 14(16).

PMID: 36010954 PMC: 9405909. DOI: 10.3390/cancers14163961.

References

Zhang B, Yang B, Tang Z . Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130(7):417-22. DOI: 10.1007/s00432-004-0552-0. View

Marks R, Ryan A, Heba E, Tang A, Wolfson T, Gamst A . Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol. 2015; 204(3):527-35. DOI: 10.2214/AJR.14.12986. View

Lee Y, Lee J, Lee J, Lee H, Park B, Kim Y . Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology. 2015; 275(1):97-109. DOI: 10.1148/radiol.14140690. View

Kim H, Kim K, Choi J, Lee J, Lee C, Kang T . Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol. BMC Cancer. 2017; 17(1):877. PMC: 5740703. DOI: 10.1186/s12885-017-3819-y. View

Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Del Poggio P . Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. J Hepatol. 2012; 56(5):1089-1096. DOI: 10.1016/j.jhep.2011.11.022. View

Singal A, Volk M, Waljee A, Salgia R, Higgins P, Rogers M . Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009; 30(1):37-47. PMC: 6871653. DOI: 10.1111/j.1365-2036.2009.04014.x. View

Bennett G, Krinsky G, Abitbol R, Kim S, Theise N, Teperman L . Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. AJR Am J Roentgenol. 2002; 179(1):75-80. DOI: 10.2214/ajr.179.1.1790075. View

Han S, Choi J, Park M, Choi M, Eun Rha S, Lee Y . The Diagnostic Performance of Liver MRI without Intravenous Contrast for Detecting Hepatocellular Carcinoma: A Case-Controlled Feasibility Study. Korean J Radiol. 2018; 19(4):568-577. PMC: 6005954. DOI: 10.3348/kjr.2018.19.4.568. View

Arguedas M, Chen V, Eloubeidi M, Fallon M . Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003; 98(3):679-90. DOI: 10.1111/j.1572-0241.2003.07327.x. View

10.

Heimbach J, Kulik L, Finn R, Sirlin C, Abecassis M, Roberts L . AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017; 67(1):358-380. DOI: 10.1002/hep.29086. View

11.

Ghouri Y, Mian I, Rowe J . Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 2017; 16:1. PMC: 5490340. DOI: 10.4103/jcar.JCar_9_16. View

12.

Fattovich G, Stroffolini T, Zagni I, Donato F . Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127(5 Suppl 1):S35-50. DOI: 10.1053/j.gastro.2004.09.014. View

13.

Choi J, Lee J, Sirlin C . CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014; 272(3):635-54. PMC: 4263631. DOI: 10.1148/radiol.14132361. View

14.

Yu N, Chaudhari V, Raman S, Lassman C, Tong M, Busuttil R . CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol. 2010; 9(2):161-7. DOI: 10.1016/j.cgh.2010.09.017. View

15.

Sarasin F, Giostra E, Hadengue A . Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996; 101(4):422-34. DOI: 10.1016/S0002-9343(96)00197-0. View

16.

Kim H, An J, Park J, Park S, Lim Y, Lee E . Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis. Hepatology. 2018; 69(4):1599-1613. DOI: 10.1002/hep.30330. View

17.

Singal A, Marrero J, Yopp A . Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw. 2014; 12(3):375-82. PMC: 5606237. DOI: 10.6004/jnccn.2014.0039. View

18.

Omata M, Cheng A, Kokudo N, Kudo M, Lee J, Jia J . Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017; 11(4):317-370. PMC: 5491694. DOI: 10.1007/s12072-017-9799-9. View

19.

Kim S, An J, Lim Y, Han S, Lee J, Byun J . MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. JAMA Oncol. 2016; 3(4):456-463. PMC: 5470420. DOI: 10.1001/jamaoncol.2016.3147. View

20.

Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D . Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006; 101(3):513-23. DOI: 10.1111/j.1572-0241.2006.00467.x. View